10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ATF7 Antibody (C-Terminus)
Goat Polyclonal Antibody
Catalog # ALS12436

Specification

ATF7 Antibody (C-Terminus) - Product Information

Application	**IHC**
Primary Accession	P17544
Reactivity	**Human, Mouse, Rat, Rabbit, Hamster, Monkey, Pig, Horse, Bovine, Dog**
Host	**Goat**
Clonality	**Polyclonal**
Calculated MW	**53kDa KDa**

ATF7 Antibody (C-Terminus) - Additional Information

Gene ID 11016

Other Names
Cyclic AMP-dependent transcription factor ATF-7, cAMP-dependent transcription factor ATF-7, Activating transcription factor 7, Transcription factor ATF-A, ATF7, ATFA

Target/Specificity
Human ATF7. This antibody is expected to recognise all three reported isoforms (NP_001123531.1, NP_006847.1 and NP_001123532.1).

Reconstitution & Storage
Store at -20°C. Minimize freezing and thawing.

Precautions
ATF7 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

ATF7 Antibody (C-Terminus) - Protein Information

Name ATF7

Synonyms ATFA

Function
Stress-responsive chromatin regulator that plays a role in various biological processes including innate immunological memory, adipocyte differentiation or telomerase regulation (PubMed:29490055). In absence of stress, contributes to the formation of heterochromatin and heterochromatin-like structure by recruiting histone H3K9 tri- and di-methyltransferases thus silencing the transcription of target genes such as STAT1 in adipocytes, or genes involved in innate immunity in macrophages and adipocytes (By similarity). Stress induces ATF7 phosphorylation that disrupts interactions with histone methyltransferase and enhances the association with coactivators containing histone

acetyltransferase and/or histone demethylase, leading to disruption of the heterochromatin-like structure and subsequently transcriptional activation (By similarity). In response to TNF-alpha, which is induced by various stresses, phosphorylated ATF7 and telomerase are released from telomeres leading to telomere shortening (PubMed:29490055). Also plays a role in maintaining epithelial regenerative capacity and protecting against cell death during intestinal epithelial damage and repair (By similarity).

Cellular Location
Nucleus {ECO:0000255|PROSITE-ProRule:PRU00978, ECO:0000269|PubMed:17264123}. Nucleus, nucleoplasm. Chromosome, telomere. Note=Mainly nucleoplasmic. Restricted distribution to the perinuclear region. The sumoylated form locates to the nuclear periphery

Tissue Location
Expressed in various tissues including heart, brain, placenta, lung and skeletal muscle. Highest levels in skeletal muscle. Lowest in lung and placenta.

ATF7 Antibody (C-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

ATF7 Antibody (C-Terminus) - Images



Anti-ATF7 antibody IHC of human testis.

ATF7 Antibody (C-Terminus) - Background

Plays important functions in early cell signaling. Binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AG][AG]- 3'), a sequence present in many viral and cellular promoters. Activator of the NF-ELAM1/delta-A site of the E-selectin promoter. Has no intrinsic transcriptional activity, but activates transcription on formation of JUN or FOS heterodimers. Also can bind TRE promoter sequences when heterodimerized with members of the JUN family. Isoform 5/ATF-4 acts

as a negative regulator, inhibiting both ATF2 and ATF7 transcriptional activities. It may exert these effects by sequestrating in the cytoplasm the Thr-53 phosphorylating kinase, preventing activation.

ATF7 Antibody (C-Terminus) - References

Gaire M.,et al.Nucleic Acids Res. 18:3467-3473(1990).
Chatton B.,et al.Submitted (DEC-1990) to the EMBL/GenBank/DDBJ databases.
Pescini R.,et al.J. Biol. Chem. 269:1159-1165(1994).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Scherer S.E.,et al.Nature 440:346-351(2006).